NO981146L - Transcytotiske midler og forsterkere for medikamentleveranser - Google Patents

Transcytotiske midler og forsterkere for medikamentleveranser

Info

Publication number
NO981146L
NO981146L NO981146A NO981146A NO981146L NO 981146 L NO981146 L NO 981146L NO 981146 A NO981146 A NO 981146A NO 981146 A NO981146 A NO 981146A NO 981146 L NO981146 L NO 981146L
Authority
NO
Norway
Prior art keywords
transcytotic
enhancers
agents
drug delivery
drug
Prior art date
Application number
NO981146A
Other languages
English (en)
Other versions
NO981146D0 (no
Inventor
Andrew Derek Sutton
Asrar Bari Malik
Chinnaswamy Tiruppathi
Richard Alan Johnson
Original Assignee
Andaris Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606315.1A external-priority patent/GB9606315D0/en
Application filed by Andaris Ltd filed Critical Andaris Ltd
Publication of NO981146D0 publication Critical patent/NO981146D0/no
Publication of NO981146L publication Critical patent/NO981146L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO981146A 1995-09-21 1998-03-16 Transcytotiske midler og forsterkere for medikamentleveranser NO981146L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US409795P 1995-09-21 1995-09-21
GBGB9606315.1A GB9606315D0 (en) 1996-03-26 1996-03-26 Transcytosis vehicles and enhancers for drug delivery
PCT/GB1996/002326 WO1997010850A1 (en) 1995-09-21 1996-09-20 Transcytosis vehicles and enhancers for drug delivery

Publications (2)

Publication Number Publication Date
NO981146D0 NO981146D0 (no) 1998-03-16
NO981146L true NO981146L (no) 1998-03-16

Family

ID=26308989

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981146A NO981146L (no) 1995-09-21 1998-03-16 Transcytotiske midler og forsterkere for medikamentleveranser

Country Status (15)

Country Link
US (1) US6204054B1 (no)
EP (1) EP0851767A1 (no)
JP (1) JPH11512451A (no)
KR (1) KR19990063632A (no)
CN (1) CN1195995A (no)
AU (1) AU717329B2 (no)
BR (1) BR9610492A (no)
CA (1) CA2230479A1 (no)
CZ (1) CZ50398A3 (no)
HU (1) HUP9900017A3 (no)
NO (1) NO981146L (no)
NZ (1) NZ318472A (no)
PL (1) PL326078A1 (no)
RU (1) RU2169010C2 (no)
WO (1) WO1997010850A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
EP0806940B1 (en) 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
CA2206657C (en) 1994-12-22 2009-05-19 Astra Aktiebolag Therapeutic preparation for inhalation containing parathyroid hormone, pth
US6261787B1 (en) * 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO1998055105A1 (en) 1997-06-05 1998-12-10 Hemosphere, Inc. Fibrinogen-coated microspheres
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
GB9801070D0 (en) * 1998-01-19 1998-03-18 Andaris Ltd HIV inhibition
EP1279406A4 (en) * 2000-04-03 2007-10-24 Santen Pharmaceutical Co Ltd TRANSPORTERS AND DRUG DISPENSING SYSTEMS USING THESE
AU2002210383A1 (en) * 2000-10-16 2002-04-29 Proteopharma Aps The function of a haptoglobin-haemoglobin receptor and the uses thereof
WO2002032396A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for delivery of nucleic acids
CN1491233A (zh) * 2001-02-02 2004-04-21 康久化学公司 长效生长激素释放因子衍生物
US7067494B2 (en) * 2001-06-22 2006-06-27 The University Of British Columbia Antimitotic eleuthesides
CN1318093C (zh) * 2001-09-28 2007-05-30 参天制药株式会社 含与聚乙二醇结合的药物的眼组织注射剂
RU2350622C2 (ru) * 2001-10-05 2009-03-27 Цитос Байотекнолоджи Аг Конъюгат ангиотензиновой пептидной составляющей с носителем, композиция вакцины, способ иммунизации животного и способ лечения или профилактики физического нарушения, ассоциированного с активируемой ренином ангиотензиновой системой
RU2196604C1 (ru) * 2001-12-21 2003-01-20 Северин Евгений Сергеевич Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
WO2003059884A1 (en) * 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
RU2361615C2 (ru) * 2002-12-09 2009-07-20 Абраксис Байосайенс, Ллс. Композиции и способы доставки фармакологических агентов
CN103405405A (zh) * 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
PT1585548T (pt) * 2002-12-09 2018-10-17 Abraxis Bioscience Llc Composições e métodos de administração de agentes farmacológicos
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
WO2007067596A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
EP2253326B1 (en) * 2008-02-28 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for transnasal administration
US20100166808A1 (en) * 2008-11-17 2010-07-01 Giovanni Marco Pauletti Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
WO2010065954A2 (en) * 2008-12-05 2010-06-10 Abraxis Bioscience, Llc Sparc binding peptides and uses thereof
CA2777628C (en) 2009-10-16 2019-12-03 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
WO2011074578A1 (ja) 2009-12-14 2011-06-23 国立大学法人北海道大学 脂質膜構造体に細胞透過能を付与および／または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体
EP2616045B1 (en) * 2010-09-15 2017-10-25 Randall J. Mrsny Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
WO2014197546A1 (en) * 2013-06-04 2014-12-11 The Johns Hopkins University Therapeutic strategy via controllable transepithelial delivery of therapeutics and diagnostics
CA2959660A1 (en) 2014-09-03 2016-03-10 Genesegues, Inc. Therapeutic nanoparticles and related compositions, methods, and systems

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB737961A (en) * 1952-08-14 1955-10-05 Roskilde Medical Company Ltd Method for the production of insulin preparations with protracted effect
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5254342A (en) * 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993020834A1 (en) 1992-04-10 1993-10-28 Brigham And Women's Hospital Methods and compositions for oral delivery of therapeutic agents

Also Published As

Publication number Publication date
MX9802286A (es) 1998-08-30
JPH11512451A (ja) 1999-10-26
EP0851767A1 (en) 1998-07-08
AU6995796A (en) 1997-04-09
NZ318472A (en) 1999-10-28
CN1195995A (zh) 1998-10-14
CZ50398A3 (cs) 1998-07-15
AU717329B2 (en) 2000-03-23
KR19990063632A (ko) 1999-07-26
HUP9900017A3 (en) 2001-08-28
NO981146D0 (no) 1998-03-16
PL326078A1 (en) 1998-08-17
HUP9900017A2 (hu) 1999-04-28
RU2169010C2 (ru) 2001-06-20
US6204054B1 (en) 2001-03-20
BR9610492A (pt) 1999-03-30
WO1997010850A1 (en) 1997-03-27
CA2230479A1 (en) 1997-03-27

Similar Documents

Publication Publication Date Title
NO981146L (no) Transcytotiske midler og forsterkere for medikamentleveranser
DK1009454T3 (da) Dental bedövelsesmiddel og tilförselsinjektionsenhed
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
FI950130A7 (fi) Jauhemainen lääkkeen moniannoksinen antolaite ja siihen liittyvä menetelmä
DE69620549D1 (de) Intravaginale Freisetzungsvorrichtung für Medikamente
NO982613D0 (no) Legemiddelavleveringsanordning
LU91138I2 (fr) Glulisine d'insuline et ses dérivés pharmaceutiquement acceptables.
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
FI972586L (fi) Lääkeainesuspension säädellysti vapauttava antolaite
DE69816325D1 (de) Gepufferte arzneistoffformulierungen zur transdermalen verabreichung durch elektrotransport
EE9800025A (et) Transkorneaalne süsteem ravimite manustamiseks
DE69531788D1 (de) Verbessertes bioadhäsives pharmazeutisches abgabesystem
NO20000735D0 (no) Legemiddel leveringsanordning for vedvarende frigivelse
FI971279A0 (fi) Lääkkeitä
DE69823583D1 (de) Kassette und Kassetenliefersystem
NO980546D0 (no) Farmasöytiske midler
DE69828895D1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
DE69430699D1 (de) Medikamente abgebende stents
BR9509688A (pt) Composto e composição farmacêutica
NO20002526L (no) Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav
EE9800275A (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
BR9606066A (pt) Composto e formulação farmacêutica
DE59602440D1 (de) Liefervorrichtung